Medtronic Depreciation increased by 9.2% to $308.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 14.9%, from $268.00M to $308.00M.
High depreciation relative to revenue may indicate a capital-intensive business model or significant recent investment in infrastructure.
The systematic allocation of the cost of tangible assets over their useful lives. This non-cash expense reflects the wea...
Standard accounting metric across all capital-intensive industries.
other_depreciation| Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | Q2 '26 | Q3 '26 | |
|---|---|---|---|---|---|---|
| Value | $248.00M | $262.00M | $268.00M | $289.00M | $282.00M | $308.00M |
| QoQ Change | — | +5.6% | +2.3% | +7.8% | -2.4% | +9.2% |
| YoY Change | — | — | — | +16.5% | +7.6% | +14.9% |
| Segment | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Diabetes | $23.50M | $24.00M | $27.00M | $30.00M | $31.00M | $31.00M | $32.00M | $32.00M |
| Cardiovascular | $49.75M | $55.00M | $56.00M | $56.00M | $58.00M | — | — | — |
| Medical Surgical | — | — | — | — | $53.00M | — | — | — |
| Neuroscience | — | — | — | — | $72.00M | — | — | — |
| Other operating segment | — | — | — | — | — | — | — | $0.00 |
| Total | — | $248.00M | $262.00M | $268.00M | — | $289.00M | $282.00M | $308.00M |